New drug for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug for people with a rare type of lung cancer called large-cell neuroendocrine carcinoma (LCNEC). It is for those with advanced cancer that can't be cured, and who have just started standard chemotherapy. The drug is given after one cycle of chemo and may help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with large-cell neuroendocrine carcinoma (LCNEC) of the lung, or a mix where LCNEC is at least half of the cancer.
- Your cancer is advanced (has spread or can't be removed) and can't be cured with standard treatments.
- You have already received at least one cycle of a type of chemotherapy called platinum/etoposide (with or without an immunotherapy drug), but no more than one cycle.
- You have not had any other prior treatment for your metastatic cancer, and have not previously taken obrixtamig or any other drug targeting DLL3.
- If you have brain metastases, they must be stable and not causing symptoms, and you must not be on steroids for at least 3 weeks.
- You have measurable disease (as determined by scans like CT or MRI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare type of cancer called LCNEC or EP-NEC that has spread. The goal is to see if this combination can help shrink or control the cancer and improve outcomes.
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
This study tests a new combination of two investigational drugs, obrixtamig and ZL-1310, for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
Hear when a new Large Cell Neuroendocrine Carcinoma of the Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.